carbamazepine
carbamazepine: sourced relationships with 1 company · 8 clinical trials tracked · 1 FDA decision.
carbamazepine evidence translation
What we can confirm
1 FDA record · 8 tracked trials
What it means
What to watch
Prepared research question
How could carbamazepine → ANIP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 5 study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ANI PHARMACEUTICALS INC (ANIP) Reported 2011-05-20 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (8)
A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants
Primary endpoint: Cohort 1: Pharmacokinetics (AUC 0-last)
A Phase 1 Crossover Design Study to Assess the Effect of CYP3A Moderate and Strong Inhibitors (Fluconazole and Itraconazole) and Strong Inducer (Carbamazepine) on the Single-dose Pharmacokinetics of ASP3082 in Healthy Adults
Primary endpoint: Pharmacokinetics (PK) of ASP3082 in plasma: Maximum Concentration (Cmax) in ASP3082
A Phase 1, Open-Label Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB123667
A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants
Primary endpoint: Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Mavorixafor Without (Day 1) and With (Day 18) Coadministration With Carbamazepine
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine, and Fluconazole on the Pharmacokinetics and Safety of EDP-323 in Healthy Participants
Primary endpoint: Cmax of EDP-323 with and without coadministration with Itraconazole
A Drug-Drug Interaction Study to Assess the Effect of Carbamazepine on the Pharmacokinetics of Orforglipron in Healthy Participants
Primary endpoint: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-∞]) of Orforglipron
A Phase 1, Single-Center, Open-Label, 3-Cohort, Fixed-Sequence, Drug-Drug Interaction Study To Assess The Pharmacokinetics Of LY4100511 (DC-853) When Orally Administered Alone, When Coadministered With Itraconazole, Fluconazole, Or Carbamazepine In Healthy Adult Participants
Primary endpoint: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4100511 (DC-853)
An Interventional, Phase 1, Open-Label, Fixed Sequence, 2-Period Study to Estimate the Effect of Multiple Doses of Carbamazepine on the Pharmacokinetics of Single Dose Vepdegestrant (ARV-471, PF-07850327) 200 mg Under the Fed Condition in Healthy Adult Males and Females of Nonchildbearing Potential
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant when administered alone
Frequently asked questions
Which companies have sourced relationships with carbamazepine?
carbamazepine has dated SEC/FDA relationship records for ANI PHARMACEUTICALS INC.
How many clinical trials involve carbamazepine?
BioSniper tracks 8 clinical trials involving carbamazepine.
What is carbamazepine's latest FDA decision?
The most recent tracked FDA decision for carbamazepine is Approval, dated May 20, 2011.